Depatuxizumab mafodotin
Depatuxizumab mafodotin carried a cell-killing payload to glioblastomas with extra copies of the EGFR gene. It caused serious eye problems and, in the phase 3 INTELLANCE-1 trial, did not help patients live longer, so development stopped in 2019.
Overview
Depatuxizumab mafodotin (ABT-414) was AbbVie's antibody-drug conjugate for EGFR-amplified glioblastoma, present in roughly 40 to 50 percent of cases. The antibody binds EGFR only where it is overexpressed or mutated, sparing normal tissue, and delivers monomethyl auristatin F. It was given intravenously every two weeks with radiotherapy and temozolomide.
INTELLANCE-1 (RTOG 3508), a phase 3 trial in newly diagnosed EGFR-amplified glioblastoma, found no improvement in overall survival at its 2019 interim analysis and enrolment stopped; INTELLANCE-2, in recurrent disease, showed only a late trend. Corneal toxicity with blurred vision affected most patients. The glioblastoma page lists it among the major systemic trials that failed after temozolomide.
- Tumour cell
- Antigen (e.g. TROP2, HER2)
An antibody that binds a conformational EGFR epitope exposed on tumours with EGFR amplification or the EGFRvIII mutant, linked to the microtubule toxin monomethyl auristatin F; the conjugate is internalised and the payload stops cell division. Connects to EGFR and Tubulin (microtubules).
- Tumour cell
- Antigen (e.g. TROP2, HER2)
1.Depatuxizumab mafodotin's antibody arm binds EGFR on the surface of the cancer cell.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Depatuxizumab mafodotin" OR ABSTRACT:"Depatuxizumab mafodotin" OR TITLE:"ABT-414" OR ABSTRACT:"ABT-414" OR TITLE:"Depatux-M" OR ABSTRACT:"Depatux-M") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Depatuxizumab mafodotin, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentNeoVax
Shares Glioma & glioblastoma and the tag subtype-drugs-wave.
- TreatmentZanidatamab zovodotin
Shares Antibody-drug conjugate (ADC) and the tag subtype-drugs-wave.
- TreatmentPoziotinib
Shares EGFR and the tag subtype-drugs-wave.
- TrialA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Shares Temozolomide, Glioma & glioblastoma.
- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide, Glioma & glioblastoma.
- TrialA Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Shares Temozolomide, Glioma & glioblastoma.